April 7, 2026

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

Until recently, Virginia was rarely considered among these thriving hives of innovation for biopharma and advanced pharmaceutical manufacturing (APM).

But Virginia has always been known for its strong manufacturing base, enabled by top talent and workforce solutions, reasonable operating costs, a commonsense business climate, strong energy and logistics infrastructure, and a commitment to identifying and developing sites for manufacturers. From there, the Commonwealth engineered efficiencies to navigate past obstacles and trim red tape faster and more reliably than competitors.

The upshot? In recent years, Virginia has emerged as an increasingly popular landing spot for life science projects; specifically, for launches, relocations, and expansions related to biopharma and APM.

The reasons for building and chasing that momentum are perhaps best summed up by Eli Lilly and Company CEO David Ricks’ comments from late 2025, which followed an announcement that his company would build a $5 billion, state-of-the-art cancer and autoimmune therapy facility in Goochland County.

By Kelly Murphy, BHI Life Sciences Business Strategist and Program Manager

At BioHealth Innovation, we have worked with hundreds of early-stage biohealth founders preparing for investor meetings, and increasingly, we are seeing AI tools enter the preparation process. When used well, AI can function like a “first-pass analyst” to quickly stress-test your narrative, identify gaps, and to help translate complex science into investor-friendly language. But while AI can accelerate early feedback cycles, it is not a substitute for deep domain expertise, investor insight, or strategic judgement that can be provided by experienced entrepreneurs and analysts. Knowing where it adds value and where it falls short is what separates founders who use it effectively from those who are lulled into a false sense of readiness.

What AI Can Do Well

AI excels at structure, clarity, and pattern recognition. For early-stage companies, this can be a major advantage.

First, AI can help ensure your pitch deck tells a coherent story. Many technical founders struggle to translate highly specialized science into a compelling narrative for an investor audience. AI can quickly flag when your problem...

Beginning in 2023, Novavax embarked on an identity shift, moving away from the fully integrated business ambitions once fueled by a pandemic-era gold rush in vaccines toward a leaner structure built on an “amplification strategy.” After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its Matrix-M vaccine adjuvant as a versatile, license-ready asset for other biopharma companies like Sanofi and Pfizer.

“The best way to increase access to our technology platform is to put it in the hands of partners, right?” Silvia Taylor, Novavax’s chief corporate affairs officer and head of Sweden operations, said in a recent interview with Fierce on the sidelines of the World Vaccines Congress Washington 2026. “It’s like an amplification strategy.”

Novavax once had grander plans. The COVID-19 pandemic presented a rare opportunity for the biotech to become a fully integrated commercial player like BioNTech and Moderna. 

By Catherine Leasure, Ph.D., BHI Life Sciences Business Strategist – If you’ve written a grant recently, you’ve probably wondered whether AI could make the process easier. Maybe you’ve already tried it. The honest answer is that AI can help, but how much depends entirely on what you bring to it. When you know what you’re doing, it gets you to a solid draft faster. However, without a strong grasp of the process behind it, it can produce polished-sounding text that misses the mark in ways that aren’t always obvious until a reviewer or experienced grant writer points them out.

Where AI Earns Its Keep

The tasks where AI performs best are the ones that are time-consuming but relatively mechanical. Generating a document outline that accounts for both grant requirements and your specific project content is a good example. What might take an hour of cross-referencing a funding opportunity announcement can be done in minutes with the right prompt. From there, AI can help turn that outline into a working first draft and translate dense technical language into plain descriptions for non-specialist reviewers...

Virginia’s life sciences sector is gaining traction through a network of regional innovation hubs that connect research, capital, and commercialization support. This article from the Virginia Economic Development Partnership looks at how places like Charlottesville, Richmond, Roanoke-Blacksburg, Hampton Roads, and Northern Virginia are helping turn scientific research into growing companies, with Contraline’s progress in male contraception offering one example of that momentum in action.

Rather than relying on a single flagship city or institution, the story highlights a statewide approach built on collaboration among universities, health systems, incubators, and public investment. It is a useful look at how Virginia is trying to create the conditions for more startups to launch, scale, and stay rooted in the Commonwealth.

Incheon, S. Korea and Maryland, United States, March 31, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

BioBuzz Networks, Inc. and Heffron Company, Inc. have entered into a multi-year strategic partnership focused on supporting the continued growth of the life sciences industry through expanded community engagement, storytelling, and workforce development.

The partnership reflects a shared belief that the success of the life sciences ecosystem depends not only on scientific discovery, and facilities built and run with patience in mind, but also on the broader network of companies, skilled professionals, and infrastructure that make commercializing new medicines possible.

Over the next three years, the organizations will work together to bring greater visibility to the many contributors who help power the life sciences industry — particularly the skilled trades, professionals and companies responsible for building and maintaining the specialized environments where discovery happens.

Heffron Company has played a foundational role in supporting this infrastructure for over 104 years. The firm is widely respected for its work in mechanical contracting, high-purity piping, plumbing, and facility services...

Montgomery County, MD – The Montgomery County Economic Development Corporation (MCEDC) today announced Jessica Reynolds as its new Chief Operating Officer, marking a strategic addition to its executive leadership team at a pivotal time for the County’s economic growth and global competitiveness.

As Montgomery County continues to strengthen its position as a leading destination for life sciences, advanced technology, and innovation, Reynolds will play a critical role in driving operational excellence, advancing strategic initiatives, and deepening partnerships that support business growth and investment across the region.

Reynolds joins MCEDC from the Maryland Department of Commerce, where she most recently served as Senior Director of the Office of International Investment and Trade (OIIT). In this role, she led the State’s international investment and export efforts for seven years, helping to expand Maryland’s foreign direct investment strategy and launch key initiatives such as the Maryland Innovation Lab, Global Gateway Program, and Soft Landing Exchange Program. Under her leadership, OIIT was awarded the prestigious President’s E Star Award for Export Service in 2021.

The Quantum BioTechnology Conference (QBT26) aims to highlight the current state of the art in quantum sensing, quantum reporters, quantum control, and quantum analysis of complex, large scale biological data and to identify opportunities in technology development.

To bridge the gap from innovation to impact, the conference will determine the needs of the biomedical community for improved sensing, reporting, control, and analysis capabilities. Our goal is to identify the most pressing needs in national workforce development in quantum information science and engineering, a field identified as critical to U.S. technological leadership.

Register now for Georgetown University’s Research & Innovation Showcase on April 22, 2026. This year’s theme, Partnerships Power Possibilities, highlights how collaboration turns research into real-world impact.

Hosted by the Office of Technology Commercialization with the Office of Advancement and Georgetown Entrepreneurship, the event features a day of learning, networking, and recognition, including a panel, reverse pitch, awards, and a New Venture Showcase.

The afternoon showcase will feature startups backed by Georgetown research, students, and alumni, with a focus on sustainability, health equity, and artificial intelligence. Building on Georgetown breakthroughs such as the whole-body CT scanner, Allegra, and Gardasil, this year’s research points to the next generation of solutions.

The event runs from 10 a.m. to 7:30 p.m. at Lohrfink Auditorium in the Rafik B. Hariri Building on Georgetown’s campus. Read more about the showcase and agenda here.

AURP Brings Industry Leaders to Manassas for Immersive Innovation Experience

The Association of University Research Parks (AURP) will host its Insights Into Research Parks program in Manassas, Virginia, on April 22–23, 2026, offering a hands-on look at the innovation ecosystem anchored by George Mason University.

This two-day experience is designed for thought leaders, economic developers, research park professionals, and university and industry partners seeking practical insight into how research-driven communities grow and succeed. Attendees will explore the infrastructure, partnerships, and culture that support research, commercialization, and regional economic development.

Participants will gain direct exposure to the Innovation District surrounding George Mason University’s Science...

USP (U.S. Pharmacopeia) is pleased to host an upcoming public event, Advancing U.S. Health Security: Scaling Innovative Solutions for Medicines Supply Chain Resiliency, where we will evaluate levers and scalable, innovative solutions that build a more resilient pharmaceutical supply chain.

Building on USP’s recent launch of the USP Resiliency Center, where we grounded our understanding of the U.S. medicine supply chain in end-to-end data and visibility, our speakers and panelists will discuss next steps to solve challenges and scale solutions for U.S. medicine supply chain resiliency.

The event will be hosted in-person at USP’s Rockville office, with the option to attend virtually as well. Breakfast and lunch will be provided for in-person attendees.

BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

“Securing Fast Track designation for SIM0505 validates the urgent, unmet need for new treatments for platinum resistant ovarian cancer and enables us to work more closely with FDA to accelerate development. We believe this designation will help to streamline and de-risk development through proactive and ongoing engagement with...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list.

“We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For,” said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. “This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients through the development of novel therapeutics and progress toward an unlimited supply of transplantable organs.”

At the top of the list are Stanford University at $415 billion, Harvard University at $326 billion, and MIT at $258 billion. The rankings reflect the combined exit value of companies founded by alumni from each institution, based on exited U.S. unicorns with valid exit values across a large multi-decade dataset.

What makes the list especially interesting is how broadly innovation is distributed. While global brand names are well represented, several universities stand out for performing beyond what many might expect. Public institutions also show strong results, with Berkeley, UCLA, Michigan, Illinois, UC Santa Barbara, Maryland, Arizona State, and the University of Washington all appearing in the top 25.

For those of us in the BioHealth Capital Region, one point is especially worth noting: the University of Maryland ranks in the top 25 with $56 billion in total founder exit value and Georgetown University with $46B. That is another reminder that this region is home to institutions with real impact, not only in research and talent development, but also in building companies that create lasting market value.

GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis (RRP) and other diseases, is making progress on that front, announcing it has seen "robust uptake" in usage of PAPZIMEOS (zopapogene imadenovec-drba), since launching the immunotherapy in August 2025. What's more, the company announced that the Centers for Medicare & Medicaid Services (CMS) assigned J-code J3404 to the therapy effective April 1, 2026, which will streamline reimbursement and broaden access to the treatment.

"In the short time since early and full approval, the standard-of-care first-line treatment is seeing tremendous progress," said Precigen's President and CEO, Helen Sabzevari, during a conference call to discuss fourth quarter results. "This substantial advancement constitutes a pivotal milestone for all stakeholders impacted by RRP." As a result of the interest in...